GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Nhu Co Ltd (SZSE:002001) » Definitions » EV-to-EBIT

Zhejiang Nhu Co (SZSE:002001) EV-to-EBIT : 16.82 (As of May. 24, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Zhejiang Nhu Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Zhejiang Nhu Co's Enterprise Value is ¥65,359 Mil. Zhejiang Nhu Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥3,886 Mil. Therefore, Zhejiang Nhu Co's EV-to-EBIT for today is 16.82.

The historical rank and industry rank for Zhejiang Nhu Co's EV-to-EBIT or its related term are showing as below:

SZSE:002001' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.27   Med: 15.55   Max: 38.04
Current: 16.82

During the past 13 years, the highest EV-to-EBIT of Zhejiang Nhu Co was 38.04. The lowest was 7.27. And the median was 15.55.

SZSE:002001's EV-to-EBIT is ranked better than
50.3% of 670 companies
in the Drug Manufacturers industry
Industry Median: 17.12 vs SZSE:002001: 16.82

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Zhejiang Nhu Co's Enterprise Value for the quarter that ended in Mar. 2024 was ¥56,666 Mil. Zhejiang Nhu Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥3,886 Mil. Zhejiang Nhu Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 6.86%.


Zhejiang Nhu Co EV-to-EBIT Historical Data

The historical data trend for Zhejiang Nhu Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Nhu Co EV-to-EBIT Chart

Zhejiang Nhu Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.24 17.08 15.13 13.51 16.08

Zhejiang Nhu Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.23 14.54 15.87 16.08 14.58

Competitive Comparison of Zhejiang Nhu Co's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Nhu Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Nhu Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Nhu Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Zhejiang Nhu Co's EV-to-EBIT falls into.



Zhejiang Nhu Co EV-to-EBIT Calculation

Zhejiang Nhu Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=65359.451/3886.17
=16.82

Zhejiang Nhu Co's current Enterprise Value is ¥65,359 Mil.
Zhejiang Nhu Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3,886 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang Nhu Co  (SZSE:002001) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Zhejiang Nhu Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=3886.17/56666.2777
=6.86 %

Zhejiang Nhu Co's Enterprise Value for the quarter that ended in Mar. 2024 was ¥56,666 Mil.
Zhejiang Nhu Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3,886 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang Nhu Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Zhejiang Nhu Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Nhu Co (SZSE:002001) Business Description

Traded in Other Exchanges
N/A
Address
No. 4 Jiangbei Road, Yulin Street, Xinchang County, Zhejiang Province, Shaoxing, CHN, 312500
Zhejiang Nhu Co Ltd is a China-based company engaged in the manufacture and sales of pharmaceuticals, health protection products, pharmaceutical intermediates, fragrances, food additives and feed additives. The company's active pharmaceutical ingredient products cover various areas such as Cardiovascular, Anti-AIDS, Anti-cancer and Anti-bacterial with key products such as Latamoxef Sodium, Flomoxef Sodium, Hydrochloride Moxifloxacin, Artemisinin series, Calcium Keto acid series, Vitamin A/E/D3 and coenzyme Q10 and others. The other business areas are Aroma chemicals, Polymers, and Nutrition. The organization markets its products in China and internationally.
Executives
Hu Bai Fan Director
Shi Guan Qun Directors, Directors, and Executives
Hu Bai Shan Directors, executives
Cui Xin Rong Director
Chen Xue Cao Supervisors
Zhou Gui Yang Director
Qiu Jin Zhuo Supervisors
Wang Xue Wen Directors, executives
Wang Zheng Jiang Director
Ye Yue Heng Director
Dong Xiao Fang Supervisors
Liang Xiao Dong Supervisors
Zhang Xiao Bo Supervisors
Wang Xu Lin Supervisors
Ding Zhong Jun Director

Zhejiang Nhu Co (SZSE:002001) Headlines

No Headlines